OpenScience.ink

2 weeks ago • European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society

Possible effects of glucagon-like peptide-1 receptor drugs on recovery after spine surgeryCan glucagon-like peptide-1 receptor agonists affect outcomes after spine surgery? A systematic review and meta-analysis.

📖 Top 20% Journal

2 weeks ago • Nutrition, metabolism, and cardiovascular diseases : NMCD

Heart disease outcomes linked to semaglutide and tirzepatide in type 2 diabetes and obesity: a comprehensive reviewCoronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.

2 weeks ago • medRxiv : the preprint server for health sciences

GLP Medications and Risk of Severe Long COVID in People with Type 2 DiabetesGLP Medications and Severe Post-COVID-19 Outcomes Among Individuals with Type 2 Diabetes Mellitus.

2 weeks ago • Frontiers in endocrinology

Heart protection from incretin therapies beyond diabetes: evidence, how they work, and new treatment options from GLP-1 drugs to combined therapiesIncretin-based cardiovascular protection beyond diabetes: evidence, mechanisms, and therapeutic frontiers from GLP-1 receptor agonists to multi-agonist therapy.

🎖️ Top 10% Journal

2 weeks ago • Nutrition, metabolism, and cardiovascular diseases : NMCD

Using semaglutide to manage heart disease in overweight and obese patients: expert adviceManagement of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use.

2 weeks ago • Surgical endoscopy

Changes in weight-loss surgery use after semaglutide and tirzepatide became popularEvolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide.

📖 Top 20% Journal

2 weeks ago • Cell reports

Modified GLP1R activators favor G protein signaling by shifting a specific outer receptor loopN-terminally modified GLP1R agonists drive G protein bias via extracellular loop 3 displacement.

🥈 Top 2% Journal

2 weeks ago • Cureus

Urinary Problems Linked to Severe Obesity and How Weight Loss Surgery and Diabetes Drugs May Help Manage ThemUrological Complications of Morbid Obesity and the Role of Bariatric Surgery and Glucagon-Like Peptide-1 Receptor Agonists in Their Management: A Systematic Review.

2 weeks ago • Diabetologia

Drug treatment for metabolic dysfunction-associated fatty liver diseasePharmacological treatment of MASH.

🥈 Top 2% Journal

2 weeks ago • Journal of the American Heart Association

🥉 Top 5% Journal

2 weeks ago • JAMA health forum

Compounded GLP-1 Receptor Agonist Use After Shortages in Two States with Likely High DemandPostshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand.

🥉 Top 5% Journal

2 weeks ago • Cureus

Genetic Study Across Populations Links a Blood Sugar Regulator to Antipsychotic Drug Metabolic RisksMulti-ancestry Transcriptome-Wide Association Study (TWAS)-Informed Prioritization of Antipsychotic Metabolic Risk: Evaluation of GLP1R as a Shared Mechanistic Link.

2 weeks ago • BMC endocrine disorders

Short-term tirzepatide treatment and its link to average platelet size in people with obesityEffect of short-term tirzepatide treatment on mean platelet volume in patients with obesity: a retrospective controlled study.

📖 Top 20% Journal

← prevpage 8 of 14next →

Latest GLP-1 Therapies Research Papers